Aeglea Bio Therapeutics (NASDAQ:AGLE) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.12), Fidelity Earnings reports.
Shares of AGLE opened at $7.87 on Friday. The firm’s 50 day moving average is $7.80 and its 200-day moving average is $7.36. The company has a quick ratio of 8.44, a current ratio of 8.44 and a debt-to-equity ratio of 0.05. Aeglea Bio Therapeutics has a 12-month low of $5.99 and a 12-month high of $9.64.
AGLE has been the topic of several recent research reports. ValuEngine raised shares of Aeglea Bio Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. BidaskClub raised shares of Aeglea Bio Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $14.33.
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Featured Story: The Role of a Fiduciary and Individual Investors
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.